Condition
Stage IV Intraocular Melanoma
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 2 (3)
Trial Status
Terminated2
Completed2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01413191Phase 2Completed
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye
NCT01533948Phase 2Terminated
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
NCT01730157Early Phase 1Terminated
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
NCT00085189Phase 2Completed
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Showing all 4 trials